Phathom Pharmaceuticals (PHAT) 3rd Annual Guggenheim Healthcare Innovation Conference summary

Commercial performance

• FY2026 revenue guidance $310–$325 million, up from $175 million last year; management cited ~70% growth YoY in the third commercialization year.

• Positive cash flow reported over the last two quarters; operating profitability achieved excluding stock-based compensation, with results near breakeven including it.

GI market and prescriber strategy

• Q3 volume was 380,000 TRx fills, with 75% from GI; 250,000–300,000 prescriptions represented a >1 million annualized GI run rate.

• GI opportunity spans 20 million annual PPI and H2-blocker prescriptions; current reach was estimated at 5%, while 20%–30% penetration could support >$1 billion in GI revenue.

• The 24,000-prescriber GI universe is broadly reached, most have prescribed, and 70% of sales calls generate 75% of scripts; growth centers on deeper GI use and new primary-care writers.

• Over the next 1–2 years, growth is expected from deeper GI use and primary-care expansion; primary care is expected to become a larger business over time.

• Management described a second potential $1 billion revenue opportunity in primary care, including severe heartburn inadequately treated with PPIs and patients seeking as-needed therapy.

Access and commercial outlook

• Access First shifts GI sales calls from efficacy messaging to prescription access; BlinkRx supports prior authorizations, appeals, a $0 copay for covered patients, and a cash-pay option.

• Cash scripts were ~35% of prescriptions; management expects the share to trend down gradually, if at all, and described no forecast of a substantial change.

• 2027 guidance is expected with the Q4 earnings call; management cited continued new-patient starts and a growing shift to BlinkRx, with access and persistence benefits building over multiple quarters.